CMS Suggests “Pay For Performance” Approach To Cancer Drug Coverage
Executive Summary
The ideal approach to cancer drug reimbursement would tie payment to patient outcomes, Centers for Medicare & Medicaid Services Administrator Mark McClellan said June 15 at a Manhattan Institute luncheon in New York
You may also be interested in...
PhRMA’s Evidence-Based Medicine Principles Emphasize Individual Decisions
The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians
PhRMA’s Evidence-Based Medicine Principles Emphasize Individual Decisions
The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians
J&J Eyes Cost-Effectiveness In R&D; Scientists Trained In Health Economics
Johnson & Johnson is training its drug discovery scientists in pharmacoeconomics as one way to help contain future drug costs, Pharmaceutical R&D Chairman Per Peterson said during the company's R&D day in New York May 26